SLA: Preliminary Findings of BrainStorm’s Phase IIa Study Reported as “Extremely Optimistic”
BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Prof. Dimitrios Karussis, Principal Investigator of the Company’s clinical trials at Hadassah Medical Center in Jerusalem, presented some of his preliminary findings from the ongoing Phase IIa dose-escalating trial evaluating the company’s NurOwn™ technology, at the 24th International Symposium on ALS/MND last week in Milan, Italy.
According to Prof. Karussis, the safety data are “impressively positive,” with only minimal and transient adverse events, even though the patients in this study were injected both intrathecally and intramuscularly with up to double the dose of NurOwn cells given in the Phase I trial. In addition, a number of patients showed some initial indications of clinical improvement. “These safety observations and initial indications of clinical efficacy are extremely optimistic for the future management of ALS and the future of cell therapies for neurodegenerative diseases in general,” he commented.
As the trial is currently ongoing, the final data are not yet available for publication. At the conclusion of the trial, the company will release the complete set of data and analyses.
About BrainStorm Cell Therapeutics, Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company’s website at www.brainstorm-cell.com.
